Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study
Yi Lin, Sundar Jagannath(Mount Sinai Hospital), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Yunsi Olyslager(Janssen (Belgium)), Deepu Madduri(Johnson & Johnson (United States)), Enrique Zudaire(Centro de Investigación del Cáncer), A. Keith Stewart(Princess Margaret Hospital), Mounzer Agha(Dana-Farber Cancer Institute), Adam D. Cohen(Penn Center for AIDS Research), Jagoda Jasielec(University of Chicago), Jesús G. Berdeja(Tennessee Oncology), Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), Farah Hossain, Vickie Wang, Thomas Martin(University of California, San Francisco), Jordan M. Schecter(Centro de Investigación del Cáncer), William Deraedt(Janssen (Belgium)), Muhammad Akram(Unknown), Xiaoling Wu(South China University of Technology), Tzu‐Min Yeh(Centro de Investigación del Cáncer), Indrajeet Singh(Janssen (United States)), Marlene J. Carrasco, Alicia J. Allred(Queen's University Belfast), Dong Geng, Carolyn C. Jackson(Centro de Investigación del Cáncer)
Cited by 9
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Awareness and current knowledge of breast cancer
|Biological Research|2017|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k